Immediate Impact

5 from Science/Nature 91 standout
Sub-graph 1 of 19

Citing Papers

Synthetic Glycans to Improve Current Glycoconjugate Vaccines and Fight Antimicrobial Resistance
2022 Standout
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
2021 Standout
32 intermediate papers

Works of David N. Rubin being referenced

Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery11Supported, in part, by grant NCC9-60 from the National Aeronautics and Space Administration, Houston, Texas, Grant #9951522V from the America Heart Association Ohio Local Chapter, Columbus, Ohio and Grant #R01 HL56688-01A1 from the National Institutes of Health, Bethesda, Maryland.22Presented, in part, at the 49th Annual Scientific Sessions of American College of Cardiology, March 2000, Anaheim, California.
2001
Effect of Sulbactam on Infections Caused by Imipenem-ResistantAcinetobacter calcoaceticusBiotypeanitratus
1993

Author Peers

Author Last Decade Papers Cites
David N. Rubin 397 230 95 117 19 674
Anthony Dugard 172 122 34 107 16 668
María Luisa Martínez 187 41 21 244 25 745
Marty Allen 422 126 24 231 8 663
Leslie S.T. Fang 89 146 26 301 20 845
Nicola Galdieri 129 19 55 172 25 680
Claude E. Forkner 138 47 26 87 16 754
Jens Jensen 455 200 40 47 32 820
J. Laurence Ransom 74 156 43 109 35 641
Y. Castaing 100 26 36 103 37 741
Filippo Boroli 116 30 41 84 23 771

All Works

Loading papers...

Rankless by CCL
2026